Citations

Showing 10 of 108083 citations.

Microsurgical Resection of a Type 1 Spinal Dural Arteriovenous Fistula: A 3-Dimensional Operative Video
Aoun, Rami James N. , Sattur, Mithun G. , Krishna, Chandan , Bendok, Bernard R.

Mayo Clinic

Operative Neurosurgery | July 12, 2017 | Volume: 14 | Issue: 3 | Pages: 313-313

10.1093/ons/opx115 | PMID 29462452 Get It

Reflex Control of Nasal Blood Vessels
Nishihira, Shigeki, McCaffrey, Thomas V.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | July 12, 2017 | Volume: 96 | Issue: 3 | Pages: 273-277

10.1177/019459988709600308 | PMID 3108811 Get It

The effect of stimulation of vagal afferent fibers on nasal blood vessels was studied in 36 cats. Volume change of the nasal capacitance vessels was measured by plethysmographic balloons inserted into the nose. Electrical stimulation of the vagus nerve produced a vasodilatation of nasal mucosa. Pulmonary stretch receptor stimulation by veratridine alkaloid and progressive lung inflation in open‐chest cats also produced a vasodilatation of the nasal mucosa. These reflexes were abolished by sectioning the vagus nerves. These results suggest a reflex arc between the lung and nasal capacitance vessels which arises from pulmonary stretch receptors.
Nurse Management of Posttransplant Hypertension in Liver Transplant Patients
Schwartz, Lora, Augustine, J., RAYMER, JOANN M., Canzanello, Vincent J., Taler, Sandra J. , Textor, Stephen C.

Mayo Clinic

Journal of Transplant Coordination | July 12, 2017 | Volume: 6 | Issue: 3 | Pages: 139-144

10.1177/090591999600600308 Get It

Hypertension develops soon after organ transplantation using cyclosporine- or FK506-based immunosuppression. Sustained rises in blood pressure require intervention to reduce the risk of intracranial bleeding and other cardiovascular complications. Antihypertensive treatment is complicated by reduced renal function and potential interference with absorption and/or metabolism of cyclosporine or FK506. To manage early and long-term hypertension related to immunosuppression with cyclosporine or FK506 and prednisone following orthotopic liver transplantation, a comprehensive nurse-managed hypertension clinic was developed. Blood pressure, heart rate, and antihypertensive and immunosuppressive regimens were evaluated according to a standard protocol at 1, 4, 12, 24, and 36 months after orthotopic liver transplantation. Data indicate that posttransplantation hypertension develops within the first months after orthotopic liver transplantation and persists indefinitely. If comprehensively managed by the hypertension nurse-clinician, the percentage of controlled hypertension patients can increase over time.
Loss of clusterin shifts amyloid deposition to the cerebrovasculature via disruption of perivascular drainage pathways
Wojtas, Aleksandra, Kang, Silvia S. , Olley, Benjamin M., Gatherer, Maureen, Shinohara, Mitsuru , Lozano, Patricia A., Liu, Chia‐Chen , Kurti, Aishe, Baker, Kelsey E., Yue, Mei, Petrucelli, Leonard , Bu, Guojun , Fryer, John Denis , Wojtas, Aleksandra M, Fryer, John D., Dickson, Dennis W. , Carare, Roxana Octavia , Liu, Chia-Chen , Bu, Guojun

Mayo Clinic

Proceedings of the National Academy of Sciences | July 12, 2017 | Volume: 114 | Issue: 33 | Pages: No page available

10.1073/pnas.1701137114 | PMID 28701379 Get It

Significance Deposition of amyloid-β (Aβ) peptide in the form of parenchymal plaques and Aβ accumulation in the walls of cerebral vessels as cerebral amyloid angiopathy (CAA) are pathological hallmarks of Alzheimer’s disease (AD). The clusterin ( CLU ) gene, which confers AD risk, is associated with amyloid deposition. Here we show that loss of CLU promotes cerebrovascular CAA, yet significantly reduces the amount of parenchymal plaques by altering perivascular drainage of Aβ in the APP/PS1 mouse model of AD. The absence of CLU in these mice is associated with a lower number of hemorrhages and a decrease in inflammation. These results suggest that CLU functions as a major Aβ chaperone to maintain Aβ solubility along interstitial fluid drainage pathways and prevent CAA formation.
Ketamine for the Treatment of Depression
Rasmussen, Keith G.

Mayo Clinic

JAMA Psychiatry | July 12, 2017 | Volume: 74 | Issue: 9 | Pages: 970

10.1001/jamapsychiatry.2017.1773 | PMID 28700782 Get It

Optimal Medical Therapy for Known Coronary Artery Disease
Gibbons, Raymond J. , Miller, Todd D.

Mayo Clinic

JAMA Cardiology | July 12, 2017 | Volume: 2 | Issue: 9 | Pages: 1030

10.1001/jamacardio.2017.2249 | PMID 28700788 Get It

Comparative “nocebo effects” in older patients enrolled in cancer therapeutic trials: Observations from a 446‐patient cohort
Foster, Jared C. , Feliciano, Josephine , Seisler, Drew K., DeMatteo, Ronald P. , Lafky, Jacqueline M., Hurria, Arti , Muss, Hyman B. , Cohen, Harvey Jay, Jatoi, Aminah , Le-Rademacher, Jennifer G., Jatoi, Aminah , Le‐Rademacher, Jennifer , Gajra, Ajeet

Mayo Clinic

Cancer | July 12, 2017 | Volume: 123 | Issue: 21 | Pages: 4193-4198

10.1002/cncr.30867 | PMID 28700816 Get It

BACKGROUND A nocebo is an inert substance associated with adverse events. Although previous studies have examined the positive (placebo) effects of such inert substances, few have examined negative (nocebo) adverse event profiles, particularly in older patients who have higher morbidity and can experience frequent and severe adverse events from cancer therapy. METHODS This study focused on placebo/nocebo‐exposed patients who participated in 2 double‐blind, placebo‐controlled, cancer therapeutic studies, namely, North Central Cancer Therapy Group trial NCCTG 97‐24‐51 and American College of Surgeons Oncology Group trial Z9001, with the goal of reporting the comparative, age‐based adverse event rates, as reported during the conduct of these trials. RESULTS Among the 446 patients who received only placebo/nocebo and who were the focus of the current report, 161 were aged ≥65 years at the time of respective trial entry, and 5234 adverse events occurred. Unadjusted adverse event rates did not differ significantly between patients aged ≥65 years and younger patients (rate ratio, 1.01; 99% confidence interval, 0.47‐2.02), and the findings were similar findings for grade 2 or worse adverse events and for all symptom‐driven adverse events (for example, pain, loss of appetite, anxiety). Adjustment for sex, ethnicity, baseline performance score, and individual trial resulted in no significant age‐based differences in adverse event rates. Similar findings were observed with an age threshold of 70 years. CONCLUSIONS Adverse events are equally common in older and younger cancer patients who are exposed to nocebo and thus require the same degree of clinical consideration regardless of age. Cancer 2017;123:4193–4198. © 2017 American Cancer Society .
Patient Survey of Referral From One Surgeon to Another to Reduce Maximum Waiting Time for Elective Surgery and Hours of Overutilized Operating Room Time
Logvinov, Ilana I. , Dexter, Franklin , Dexter, Elisabeth U. , Brull, Sorin J. , Brull, Sorin J , Logvinov, Ilana

Mayo Clinic

Anesthesia & Analgesia | July 12, 2017 | Volume: 126 | Issue: 4 | Pages: 1249-1256

10.1213/ane.0000000000002273 | PMID 28704249 Get It

BACKGROUND: Studies of shared (patient-provider) decision making for elective surgical care have examined both the decision whether to have surgery and patients’ understanding of treatment options. We consider shared decision making applied to case scheduling, since implementation would reduce labor costs. METHODS: Study questions were presented in sequence of waiting times, starting with 4 workdays. “Assume the consultant surgeon (ie, the surgeon in charge) you met in clinic did not have time available to do your surgery within the next 4 workdays, but his/her colleague would have had time to do your surgery within the next 4 workdays. Would you have wanted to discuss with a member of the surgical team (eg, the scheduler or the surgeon) the availability of surgery with a different, equally qualified surgeon at Mayo Clinic who had time available within the next 4 workdays, on a date of your choosing?” There were 980 invited patients who underwent lung resection or cholecystectomy between 2011 and 2016; 135 respondents completed the study and 6 respondents dropped out after the study questions were displayed. RESULTS: The percentages of patients whose response to the study questions was “4 days” were 58.8% (40/68) among lung resection patients and 58.2% (39/67) among cholecystectomy patients. The 97.5% 2-sided confidence interval for the median maximum wait was 4 days to 4 days. Patients’ choices for the waiting time sufficient to discuss having another surgeon perform the procedure did not differ between procedures ( P = .91). Results were insensitive to patients’ sex, age, travel time to hospital, or number of office visits before surgery (all P ≥ .20). CONCLUSIONS: Our results indicate that bringing up the option with the patient of changing surgeons when a colleague is available and has the operating room time to perform the procedure sooner is being respectful of most patients’ individual preferences (ie, patient-centered).